Cargando…
National population prevalence of antibodies to SARS-CoV-2 among pregnant women in Scotland during the second wave of the COVID-19 pandemic: a prospective national serosurvey
OBJECTIVES: This study aimed to determine SARS-CoV-2 seroprevalence among pregnant women in the Scottish population during the second wave of the COVID-19 pandemic. STUDY DESIGN: Prospective national serosurvey. METHODS: We tested 13,428 residual samples retrieved from pregnant women participating i...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society for Public Health. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364809/ https://www.ncbi.nlm.nih.gov/pubmed/34517289 http://dx.doi.org/10.1016/j.puhe.2021.08.005 |
_version_ | 1783738590897897472 |
---|---|
author | McAuley, A. Gousias, P. Hasan, T. Rashid, L. Richardson, C. Reid, G. Templeton, K. McGuire, J. Wise, H. McVicar, L. Jenks, S. Gunn, R. Dickson, E. Stock, S.J. Stockton, A. Waugh, C. Wood, R. McMenamin, J. Robertson, C. Goldberg, D.J. Palmateer, N.E. |
author_facet | McAuley, A. Gousias, P. Hasan, T. Rashid, L. Richardson, C. Reid, G. Templeton, K. McGuire, J. Wise, H. McVicar, L. Jenks, S. Gunn, R. Dickson, E. Stock, S.J. Stockton, A. Waugh, C. Wood, R. McMenamin, J. Robertson, C. Goldberg, D.J. Palmateer, N.E. |
author_sort | McAuley, A. |
collection | PubMed |
description | OBJECTIVES: This study aimed to determine SARS-CoV-2 seroprevalence among pregnant women in the Scottish population during the second wave of the COVID-19 pandemic. STUDY DESIGN: Prospective national serosurvey. METHODS: We tested 13,428 residual samples retrieved from pregnant women participating in the first trimester combined ultrasound and biochemical screening for fetal trisomy across Scotland for SARS-CoV-2 antibodies over a 6-month period from November 2020 to April 2021. Seroprevalence estimates were adjusted for the sensitivity and specificity of the assays and weighted to reference populations. RESULTS: Seroprevalence rates in the antenatal samples significantly increased from 5.5% (95% confidence interval [CI] 4.7%–6.5%) in the 5-week period up to and including International Organization for Standardization (ISO) Week 51 (w/b Monday 14 December 2020) to 11.3% (95% CI 10.1%–12.6%) in the 5-week period up to and including ISO Week 14 (w/b Monday 5 April 2021). Increasing seroprevalence trends across the second wave were observed among all age groups. CONCLUSIONS: By the end of the second wave of the COVID-19 pandemic, approximately one in 10 women tested around the end of the first trimester of pregnancy had antibodies to SARS-CoV-2, suggesting that the vast majority were still susceptible to COVID-19 as they progressed to the later stages of pregnancy, when risks from infection are elevated for both mother and baby. |
format | Online Article Text |
id | pubmed-8364809 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Royal Society for Public Health. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83648092021-08-16 National population prevalence of antibodies to SARS-CoV-2 among pregnant women in Scotland during the second wave of the COVID-19 pandemic: a prospective national serosurvey McAuley, A. Gousias, P. Hasan, T. Rashid, L. Richardson, C. Reid, G. Templeton, K. McGuire, J. Wise, H. McVicar, L. Jenks, S. Gunn, R. Dickson, E. Stock, S.J. Stockton, A. Waugh, C. Wood, R. McMenamin, J. Robertson, C. Goldberg, D.J. Palmateer, N.E. Public Health Short Communication OBJECTIVES: This study aimed to determine SARS-CoV-2 seroprevalence among pregnant women in the Scottish population during the second wave of the COVID-19 pandemic. STUDY DESIGN: Prospective national serosurvey. METHODS: We tested 13,428 residual samples retrieved from pregnant women participating in the first trimester combined ultrasound and biochemical screening for fetal trisomy across Scotland for SARS-CoV-2 antibodies over a 6-month period from November 2020 to April 2021. Seroprevalence estimates were adjusted for the sensitivity and specificity of the assays and weighted to reference populations. RESULTS: Seroprevalence rates in the antenatal samples significantly increased from 5.5% (95% confidence interval [CI] 4.7%–6.5%) in the 5-week period up to and including International Organization for Standardization (ISO) Week 51 (w/b Monday 14 December 2020) to 11.3% (95% CI 10.1%–12.6%) in the 5-week period up to and including ISO Week 14 (w/b Monday 5 April 2021). Increasing seroprevalence trends across the second wave were observed among all age groups. CONCLUSIONS: By the end of the second wave of the COVID-19 pandemic, approximately one in 10 women tested around the end of the first trimester of pregnancy had antibodies to SARS-CoV-2, suggesting that the vast majority were still susceptible to COVID-19 as they progressed to the later stages of pregnancy, when risks from infection are elevated for both mother and baby. The Royal Society for Public Health. Published by Elsevier Ltd. 2021-10 2021-08-16 /pmc/articles/PMC8364809/ /pubmed/34517289 http://dx.doi.org/10.1016/j.puhe.2021.08.005 Text en © 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication McAuley, A. Gousias, P. Hasan, T. Rashid, L. Richardson, C. Reid, G. Templeton, K. McGuire, J. Wise, H. McVicar, L. Jenks, S. Gunn, R. Dickson, E. Stock, S.J. Stockton, A. Waugh, C. Wood, R. McMenamin, J. Robertson, C. Goldberg, D.J. Palmateer, N.E. National population prevalence of antibodies to SARS-CoV-2 among pregnant women in Scotland during the second wave of the COVID-19 pandemic: a prospective national serosurvey |
title | National population prevalence of antibodies to SARS-CoV-2 among pregnant women in Scotland during the second wave of the COVID-19 pandemic: a prospective national serosurvey |
title_full | National population prevalence of antibodies to SARS-CoV-2 among pregnant women in Scotland during the second wave of the COVID-19 pandemic: a prospective national serosurvey |
title_fullStr | National population prevalence of antibodies to SARS-CoV-2 among pregnant women in Scotland during the second wave of the COVID-19 pandemic: a prospective national serosurvey |
title_full_unstemmed | National population prevalence of antibodies to SARS-CoV-2 among pregnant women in Scotland during the second wave of the COVID-19 pandemic: a prospective national serosurvey |
title_short | National population prevalence of antibodies to SARS-CoV-2 among pregnant women in Scotland during the second wave of the COVID-19 pandemic: a prospective national serosurvey |
title_sort | national population prevalence of antibodies to sars-cov-2 among pregnant women in scotland during the second wave of the covid-19 pandemic: a prospective national serosurvey |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364809/ https://www.ncbi.nlm.nih.gov/pubmed/34517289 http://dx.doi.org/10.1016/j.puhe.2021.08.005 |
work_keys_str_mv | AT mcauleya nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT gousiasp nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT hasant nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT rashidl nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT richardsonc nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT reidg nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT templetonk nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT mcguirej nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT wiseh nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT mcvicarl nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT jenkss nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT gunnr nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT dicksone nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT stocksj nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT stocktona nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT waughc nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT woodr nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT mcmenaminj nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT robertsonc nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT goldbergdj nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey AT palmateerne nationalpopulationprevalenceofantibodiestosarscov2amongpregnantwomeninscotlandduringthesecondwaveofthecovid19pandemicaprospectivenationalserosurvey |